The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Circulating tumor cell kinetics in mRCC patients treated with sunitinib.
Kriti Mittal
No relevant relationships to disclose
Anthony Williams
No relevant relationships to disclose
Siddarth Rawal
No relevant relationships to disclose
Vyshak Alva Venur
No relevant relationships to disclose
Bo Lu
No relevant relationships to disclose
Jorge Torres-Munoz
No relevant relationships to disclose
Ernest C. Borden
No relevant relationships to disclose
Zheng Ao
No relevant relationships to disclose
Martin OMalley
No relevant relationships to disclose
Laura S. Wood
Honoraria - Pfizer
Siyang Zheng
No relevant relationships to disclose
Ram H Datar
Consultant or Advisory Role - Filtini
Stock Ownership - Filtini
Yu-Chong Tai
No relevant relationships to disclose
Richard J. Cote
Consultant or Advisory Role - Filtini
Stock Ownership - Filtini
Brian I. Rini
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Pfizer; Roche
Research Funding - Acceleron Pharma; Bristol-Myers Squibb; GlaxoSmithKline; Millennium; Pfizer